Trial Profile

Phase I randomized, double-blinded, placebo-controlled, single-dose, safety, tolerability, pharmacokinetic, and pharmacodynamic study in subjects with Type 2 diabetes mellitus (T2D)

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 03 May 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

03 May 2024 New trial record
26 Apr 2024 According to Hua Medicine media release, the company initiated Phase I clinical trial of its 2nd generation glucokinase allosteric activator (2nd Gen GKA) in the United States, with the successful enrollment of the first patient on 25th April 2024.
21 Dec 2023 According to Hua Medicine media release, the company submitted an Investigational New Drug (IND) application with the U.S. Food and Drug Administration for its 2nd generation glucokinase allosteric activator (2nd Gen GKA) to initiate a Phase I study in subjects with Type 2 diabetes mellitus (T2D) in the United States.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com